Novo Holdings
Novo Holdings is a leading holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. The company is the controlling shareholder of Novo Nordisk and Novonesis and manages a diverse investment portfolio with a long-term return perspective. Novo Holdings invests in life science companies at all stages of development and manages a broad portfolio of equities, bonds, real estate, infrastructure assets, and private equity investments. The firm is committed to improving people’s health and the sustainability of society and the planet by generating attractive long-term returns.
Novo Holdings
Tuborg Havnevej 19, 2900 Hellerup, Denmark
Portfolio
Aquafortus develops and commercializes novel and proprietary minimal energy resource recovery technologies for high total dissolved solids (TDS) waste and process streams.
#Technology
Breye Therapeutics is a clinical stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases.
#Biopharmaceutical
AnaCardio is developing novel drugs to treat heart failure, based on research from Karolinska Institutet.
#Biopharmaceutical
Clever Care helps members understand the complexities of their healthcare.
#Healthcare
Allievex is building a portfolio of therapeutics for rare pediatric neurodegenerative diseases.
#Biopharmaceutical
Coave Therapeutics is pioneering the development of innovative solutions to enhance genetic medicines.
#Genetic Medicine
Clario supports the capture of efficacy and safety endpoints, harmonizes data from any clinical source system, and delivers real-time insights for clinical trial performance.
#Cloud Platform Solutions
BBI is a leading supplier of products and services to the global diagnostics and life sciences industries.
#Diagnostics and Life Sciences
Anokion develops novel peptide and protein therapeutics with very low immunogenicity, focusing on orphan diseases.
#Biopharmaceutical
Availity provides digital provider engagement, clearinghouse, and revenue cycle technology solutions, connecting hospitals and physicians with health plans.
#Healthcare Technology
Avalyn is developing an improved therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
#Pharmaceutical
Precirix is developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
#Biotechnology
Alentis focuses on developing treatments for CLDN1+ tumors and organ fibrosis.
#Biotechnology
Anthos is developing and commercializing innovative therapies for high-risk cardiovascular patients.
#Biopharmaceutical
Key People
CEO
Partner, Planetary Health Investments
Senior Partner, Seed Investments
Partner, Seed Investments
Senior Partner, Venture Investments